Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 260 |
|
|||||
| News | - | ||||||
| Day High | 0.0041 | Low High |
|||||
| Day Low | 0.0041 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Acura Pharmaceuticals Inc (CE) | ACUR | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0011 | 36.67% | 0.0041 | 14:39:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0041 | 0.0041 | 0.0041 | 0.0041 | 0.003 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2 | 260 | US$ 0.0041 | US$ 1 | - | 0.000001 - 0.05 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 14:39:25 | 200 | US$ 0.0041 | USD |
Acura Pharmaceuticals Inc (CE) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 270.61k | 66.00M | 7.49M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Acura Pharmaceuticals (CE) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/14/2024 | 09:53 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/02/2024 | 09:27 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/10/2024 | 16:13 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/02/2024 | 14:23 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/02/2024 | 14:23 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/02/2024 | 14:20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/02/2024 | 14:20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 12/21/2023 | 11:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/06/2023 | 13:35 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/20/2023 | 11:08 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 11/20/2023 | 11:08 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 11/20/2023 | 11:07 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACUR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.01 | 0.01 | 0.003 | 0.0032174 | 403 | -0.0059 | -59.00% |
| 1 Month | 0.0026 | 0.05 | 0.0026 | 0.0054791 | 6,705 | 0.0015 | 57.69% |
| 3 Months | 0.001 | 0.05 | 0.001 | 0.0062653 | 3,462 | 0.0031 | 310.00% |
| 6 Months | 0.000001 | 0.05 | 0.000001 | 0.0029053 | 3,917 | 0.0041 | 409,900.00% |
| 1 Year | 0.05 | 0.05 | 0.000001 | 0.007404 | 3,574 | -0.0459 | -91.80% |
| 3 Years | 0.36 | 0.7538 | 0.000001 | 0.3500057 | 8,934 | -0.3559 | -98.86% |
| 5 Years | 0.24 | 0.7538 | 0.000001 | 0.3145245 | 9,824 | -0.2359 | -98.29% |
Acura Pharmaceuticals (CE) Description
| We are an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx Technology, a devleopment stage technology, is being developed to minimize the risk of overdose. Our Aversion Technology is intended to address methods of abuse associated with opioid analgesics and our Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Nexafed brand products utilize our Impede Technology. On June 28, 2019, we entered into License, Development and Commercialization Agreement, which was amended in October 2020 and June 2021, ("AD Pharma Agreement") with Abuse Deterrent Pharma, LLC, a Kentucky limited liability company ("AD Pharma") to develop LTX-03. The AD Pharma Agreement grants exclusive commercialization rights in the United States to LTX-03 as well as to LTX-02 (oxycodone/acetaminophen) and LTX-09 (alprazolam). The development of LTX-03 is ongoing. |
